BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20521939)

  • 1. Antimicrobial susceptibility of Gram-negative nonurinary bacteria to fosfomycin and other antimicrobials.
    Samonis G; Maraki S; Rafailidis PI; Kapaskelis A; Kastoris AC; Falagas ME
    Future Microbiol; 2010 Jun; 5(6):961-70. PubMed ID: 20521939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey.
    Demir T; Buyukguclu T
    Int J Infect Dis; 2013 Nov; 17(11):e966-70. PubMed ID: 23742831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin.
    Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Mavromanolakis E; Samonis G
    Int J Antimicrob Agents; 2010 Mar; 35(3):240-3. PubMed ID: 20034765
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility of Gram-positive non-urinary isolates to fosfomycin.
    Falagas ME; Maraki S; Karageorgopoulos DE; Kastoris AC; Kapaskelis A; Samonis G
    Int J Antimicrob Agents; 2010 May; 35(5):497-9. PubMed ID: 20226634
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial resistance of Gram-negative bacilli isolates from inpatients and outpatients at Yaounde Central Hospital, Cameroon.
    Piéboji JG; Koulla-Shiro S; Ngassam P; Adiogo D; Njine T; Ndumbe P
    Int J Infect Dis; 2004 May; 8(3):147-54. PubMed ID: 15109589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activity of fosfomycin tromethamine against extended spectrum beta-lactamase producing urinary tract bacteria.
    Khan IU; Mirza IA; Ikram A; Ali S; Hussain A; Ghafoor T
    J Coll Physicians Surg Pak; 2014 Dec; 24(12):914-7. PubMed ID: 25523727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.
    Jean SS; Hsueh PR; Lee WS; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Lam C; Chen RJ
    Int J Antimicrob Agents; 2013 May; 41(5):457-62. PubMed ID: 23507415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activity of fosfomycin against nosocomial multiresistant bacterial pathogens from Croatia: a multicentric study.
    Bielen L; Likić R; Erdeljić V; Mareković I; Firis N; Grgić-Medić M; Godan A; Tomić I; Hunjak B; Markotić A; Bejuk D; Tičić V; Balzar S; Bedenić B
    Croat Med J; 2018 Apr; 59(2):56-64. PubMed ID: 29740989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of urinary tract bacteria to fosfomycin.
    Maraki S; Samonis G; Rafailidis PI; Vouloumanou EK; Mavromanolakis E; Falagas ME
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4508-10. PubMed ID: 19687248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of tigecycline and comparators against Gram-negative pathogens isolated from blood in Europe (2004-2009).
    Andrasevic AT; Dowzicky MJ
    Int J Antimicrob Agents; 2012 Feb; 39(2):115-23. PubMed ID: 22189391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The susceptibility to fosfomycin of Gram-negative bacteria isolates from urinary tract infection in the Czech Republic: data from a unicentric study.
    Fajfr M; Louda M; Paterová P; Ryšková L; Pacovský J; Košina J; Žemličková H; Broďák M
    BMC Urol; 2017 Apr; 17(1):33. PubMed ID: 28446177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etiology, extended-spectrum β-lactamase rates and antimicrobial susceptibility of gram-negative bacilli causing intra-abdominal infections in patients in general pediatric and pediatric intensive care units--global data from the Study for Monitoring Antimicrobial Resistance Trends 2008 to 2010.
    Badal RE; Bouchillon SK; Lob SH; Hackel MA; Hawser SP; Hoban DJ
    Pediatr Infect Dis J; 2013 Jun; 32(6):636-40. PubMed ID: 23838732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro activity of fosfomycin trometamol against pathogens from urinary tract infections: a Spanish multicenter study.
    García-Rodríguez JA; Trujillano Martín I; Baquero F; Cisterna R; Gobernado M; Liñares F; Martín-Luengo F; Piédrola G
    J Chemother; 1997 Dec; 9(6):394-402. PubMed ID: 9491838
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antimicrobial susceptibility of gram-negative and gram-positive bacteria collected from countries in Eastern Europe: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) 2004-2010.
    Balode A; Punda-Polić V; Dowzicky MJ
    Int J Antimicrob Agents; 2013 Jun; 41(6):527-35. PubMed ID: 23590898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of current activities of fluoroquinolones against gram-negative bacilli using centralized in vitro testing and electronic surveillance.
    Sahm DF; Critchley IA; Kelly LJ; Karlowsky JA; Mayfield DC; Thornsberry C; Mauriz YR; Kahn J
    Antimicrob Agents Chemother; 2001 Jan; 45(1):267-74. PubMed ID: 11120976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial susceptibility of Gram-negative organisms from intraabdominal infections and evolution of isolates with extended spectrum β-lactamases in the SMART study in Spain (2002-2010).
    Cantón R; Loza E; Aznar J; Calvo J; Cercenado E; Cisterna R; Romo FG; Hontangas JL; Calvo CR; Barrenechea AI; Tubau F; Weber I; Yuste P; Cavanillas R;
    Rev Esp Quimioter; 2011 Dec; 24(4):223-32. PubMed ID: 22173194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.